A Phase I, Prospective, Randomized, Open-labeled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Booster Dose with MVC-COV1901 or MVC-COV1901(Beta) SARS-CoV-2 Vaccine in Adults

Chia En Lien, Ming-Che Liu, Ning-Chi Wang, Luke Tzu-Chi Liu, Chung-Chin Wu, Wei-Hsuan Tang, Wei-Cheng Lian, Kuan-Ying A. Huang, Charles Chen
doi: https://doi.org/10.1101/2022.08.29.22279317

Data Availability

Data sharing is not applicable to this study, as it is an interim analysis of an ongoing clinical trial.

Back to top
Posted August 31, 2022.
Download PDF

Supplementary Material

Data/Code
Email
A Phase I, Prospective, Randomized, Open-labeled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Booster Dose with MVC-COV1901 or MVC-COV1901(Beta) SARS-CoV-2 Vaccine in Adults
Chia En Lien, Ming-Che Liu, Ning-Chi Wang, Luke Tzu-Chi Liu, Chung-Chin Wu, Wei-Hsuan Tang, Wei-Cheng Lian, Kuan-Ying A. Huang, Charles Chen
medRxiv 2022.08.29.22279317; doi: https://doi.org/10.1101/2022.08.29.22279317
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area